REDWOOD CITY, Calif.–(BUSINESS WIRE)–Atreca, Inc., a biotechnology company focused on developing novel
therapeutics based on a deep understanding of the human immune response,
announced today the retirement of Susan Berland, Executive Vice
President and Chief Financial Officer (CFO), and the appointment of Herb
Cross, an accomplished senior financial executive, as her successor.
“Susan has been an invaluable part of the leadership team, and her
expertise and financial stewardship have been instrumental to our
success,” said John Orwin, President and CEO of Atreca. “We wish Susan
all the best in her retirement, and she has graciously agreed to serve
as a consultant to the Company. At the same time, we would also like to
welcome her successor, Herb Cross, a seasoned financial executive who is
well equipped to help us navigate the next phase of the Company’s growth
as our lead asset progresses into clinical development.”
Mr. Cross brings more than 20 years of experience in financial
leadership roles at both private and public biotechnology companies.
Before joining Atreca, he was the first CFO at ARMO BioSciences, leading
its initial public offering and serving in that role through the sale of
the company to Eli Lilly in 2018. Prior to this, he was the CFO at
Balance Therapeutics, leading the finance, investor relations,
information technology, and other administrative functions. Previously,
Mr. Cross was CFO and interim Chief Executive Officer at KaloBios
Pharmaceuticals, where he was responsible for overall strategic
leadership and led the finance and administrative functions. He also
served as CFO at Affymax. Earlier in his career, Mr. Cross was Vice
President, Finance at Facet Biotech Corporation, a spin-off of PDL
BioPharma, where he was Executive Director, Finance and Corporate
Controller. Mr. Cross was also the Vice President of Finance for
Neoforma and began his career at Arthur Andersen, LLP.
Mr. Cross received a Bachelor of Science in Business Administration from
the Haas School of Business at the University of California, Berkeley.
He is a certified public accountant, currently inactive, in the state of
“With Atreca poised to move its lead therapeutic candidate into the
clinic, a product of the Company’s proprietary and unique discovery
platform, this is a very exciting time to join the company,” said Herb
Cross, Chief Financial Officer of Atreca. “I am looking forward to
working with the leadership team to continue building a pipeline of
About Atreca, Inc.
Atreca is a privately held biotechnology company developing novel
therapeutics based on a deep understanding of the human immune response.
We focus in a unique way on the immune responses of patients in
therapeutic areas where such responses are the key phenomenon driving
clinical outcomes, enabling us to discover and develop novel
immunotherapies. Atreca is advancing a pipeline of candidates designed
to engage the human immune response in oncology and other indications,
thus driving better therapeutic outcomes. For more information on
Atreca, please visit www.atreca.com.
Chief Financial Officer
Steinberg, 212-213-0006, ext. 318
Flamm, 212-213-0006, ext. 364
Gray, 212-213-0006, ext. 355